<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992601</url>
  </required_header>
  <id_info>
    <org_study_id>YH16410-101</org_study_id>
    <nct_id>NCT01992601</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer</brief_title>
  <acronym>YH16410 DDI</acronym>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to compare the pharmacokinetic characteristics of combination
      and separate administration of Crestor(Rosuvastatin) and Micardis(Telmisartan). Also
      investigate drug interaction between separate and combination administration.

      Total number of subjects is 48. 4 group(12 for 1 group), 2 period, consecutive 6 day
      administration, 16 days washout after 6th day of administration.

      The subjects of Part 1 take Crestor alone and Crestor+Micardis combination by a cross-over
      design during 2 each period.

      The other subjects of Part 2 take Micardis alone and Crestor+Micardis combination by a
      cross-over design during 2 each period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>72hr</time_frame>
    <description>AUC τ,ss of Rosuvastatin and Telmisartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>72hr</time_frame>
    <description>Cmax,ss of Rosuvastatin and Telmisartan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>72hr</time_frame>
    <description>AUC last,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>72hr</time_frame>
    <description>AUC inf,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>72hr</time_frame>
    <description>Tmax,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>72hr</time_frame>
    <description>t1/2 of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>72hr</time_frame>
    <description>Cmin,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>72hr</time_frame>
    <description>AUCτ,ss of N-desmetyl Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>72hr</time_frame>
    <description>Cmax,ss of N-desmetyl Rosuvastatin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)</intervention_name>
    <description>For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.
For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 19 and 27
             kg/m2

          2. Acceptable medical history, physical examination, laboratory tests and EKG, during
             screening

          3. Provision of signed written informed consent •20~50 yrs old, healthy Korean Subjects

        Exclusion Criteria:

        1.History of and clinically significant disease 2.Sitting blood pressure meeting the
        following criteria at screening: 150 ≤ systolic blood pressure ≤90 (mmHg) and 95 ≤
        diastolic blood pressure ≤ 50 (mmHg) amd 100 ≤ Heart rate ≤ 40 3. A history of drug abuse
        or the presence of positive reactions to drugs that have abuse potential in urine
        screenings for drugs.

        4. Administration of other investigational products within 90 days prior to the first
        dosing.

        5. Administration of herbal medicine within 30 days or administration of ethical drugs
        within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior to the
        first dosing of the investigational product (if the investigator (study doctor) determines
        that the person meets other criteria appropriately, the relevant person may participate in
        the study).

        6.Have AST(SGOT) or/and ALT(SGPT) &gt; 3 times of normal upper limit at the time of screening
        7. Volunteers considered not eligible for the clinical trial by the investigator (study
        doctor) due to reasons including laboratory test results, ECGs, or vital signs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug interaction</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>(Pharmacokinetics and Drug Interaction)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

